ATE407574T2 - Fraktionen und zubereitungen aus milch zur behandlung und / oder vorbeugung cox-2 vermittelter krankheiten - Google Patents

Fraktionen und zubereitungen aus milch zur behandlung und / oder vorbeugung cox-2 vermittelter krankheiten Download PDF

Info

Publication number
ATE407574T2
ATE407574T2 AT03020739T AT03020739T ATE407574T2 AT E407574 T2 ATE407574 T2 AT E407574T2 AT 03020739 T AT03020739 T AT 03020739T AT 03020739 T AT03020739 T AT 03020739T AT E407574 T2 ATE407574 T2 AT E407574T2
Authority
AT
Austria
Prior art keywords
cox
milk
fractions
preparations
prevention
Prior art date
Application number
AT03020739T
Other languages
English (en)
Inventor
Lionel Bovetto
Joerg Hau
Catherine Mace
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130196&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE407574(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Application granted granted Critical
Publication of ATE407574T2 publication Critical patent/ATE407574T2/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/202—Casein or caseinates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
AT03020739T 2003-09-12 2003-09-12 Fraktionen und zubereitungen aus milch zur behandlung und / oder vorbeugung cox-2 vermittelter krankheiten ATE407574T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03020739.3A EP1514482B2 (de) 2003-09-12 2003-09-12 Fraktionen und Zubereitungen aus Milch zur Behandlung und / oder Vorbeugung COX-2 vermittelter Krankheiten

Publications (1)

Publication Number Publication Date
ATE407574T2 true ATE407574T2 (de) 2008-09-15

Family

ID=34130196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03020739T ATE407574T2 (de) 2003-09-12 2003-09-12 Fraktionen und zubereitungen aus milch zur behandlung und / oder vorbeugung cox-2 vermittelter krankheiten

Country Status (16)

Country Link
US (1) US8012509B2 (de)
EP (2) EP1514482B2 (de)
JP (1) JP4824560B2 (de)
CN (1) CN1849076B (de)
AR (1) AR045745A1 (de)
AT (1) ATE407574T2 (de)
AU (1) AU2004271722B2 (de)
BR (1) BRPI0413714A (de)
CA (1) CA2537544C (de)
CR (1) CR8265A (de)
DE (1) DE60323489D1 (de)
ES (1) ES2314152T3 (de)
MX (1) MXPA06002648A (de)
PT (1) PT1514482E (de)
TW (1) TW200524545A (de)
WO (1) WO2005025335A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200735781A (en) * 2005-11-14 2007-10-01 Nestec Sa Food product
NL1033698C2 (nl) * 2007-04-16 2008-10-20 Friesland Brands Bv Functioneel serumeiwitproduct voor toepassing in kindervoeding en therapeutische samenstellingen, en werkwijzen ter bereiding daarvan.
US20080293159A1 (en) * 2007-05-24 2008-11-27 Murray Goulburn Co-Operative Co. Ltd. Validation Process
AU2010306406B2 (en) * 2009-10-16 2017-12-07 Dairy Australia Limited Allergy treatment using acid treated aqueous whey protein extract
US9931365B2 (en) 2010-09-28 2018-04-03 Lisa Geng Methods for treating neurological disorders using nutrient compositions
WO2012050895A1 (en) * 2010-09-28 2012-04-19 Lisa Geng Methods for treating neurological disorders using nutrient compositions
CN105613731B (zh) * 2016-03-17 2019-12-31 广西壮族自治区水牛研究所 一种发酵乳制品
WO2019229215A2 (de) * 2018-05-30 2019-12-05 DÖHLER GmbH Hochdruckverfahren, insbesondere zur haltbarmachung von lebensmitteln, pharmazeutika und kosmetika, sowie hochdruckvorrichtung
WO2020159357A1 (en) * 2019-02-01 2020-08-06 N.V. Nutricia Native whey protein for treating and/or preventing intestinal infection

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748847A1 (de) * 1976-11-05 1978-05-11 Stauffer Chemical Co Verfahren zum verstaerken saurer alkoholfreier getraenke mit protein und verstaerkungsmittel auf proteinbasis
US4358464A (en) * 1977-08-02 1982-11-09 Superior Dairy, Inc. Process for converting sour whey into sweet whey and product
US4284623A (en) 1979-11-09 1981-08-18 Beck Lee R Method of treating inflammation using bovine milk
DE3141914A1 (de) * 1981-10-22 1983-05-05 Babcock-BSH AG vormals Büttner-Schilde-Haas AG, 4150 Krefeld Verfahren zur herstellung von frischkaese
JPS6339545A (ja) * 1986-08-04 1988-02-20 Meiji Milk Prod Co Ltd 牛乳ホエ−中のβ−ラクトグロブリンの除去方法
JP2622686B2 (ja) * 1987-05-15 1997-06-18 雪印乳業株式会社 ｋ−カゼイングリコマクロペプチドの製造法
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
US5888552A (en) 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
DE4413839C1 (de) * 1994-04-21 1995-10-19 Fritz Koch Pharma Gmbh Dr Med Kombinationspräparat
DE19649891C2 (de) * 1996-12-02 1998-12-10 Mk Produktkontor Gmbh Verwendung von antioxidativen Zusammensetzungen mit Süßmolkekonzentrat
DE19726868A1 (de) * 1997-06-24 1999-01-07 Mk Produktkontor Gmbh Antioxidative Zusammensetzungen mit Süßmolkekonzentrat
MXPA00012399A (es) * 1998-06-10 2003-07-14 Albert B Crum Complememnto nutricional profilactico y terapeutico para la creacion y mantenimiento de microflora intestinal protectora de la salud y mejoramiento del sistema inmunologico.
US6558716B1 (en) * 1999-01-14 2003-05-06 Kraft Foods Holdings, Inc. Process for incorporating whey protein into cheese
DE19918219C1 (de) * 1999-04-22 2001-01-18 Dornier Gmbh Lebensdauer-Indikator für hochbeanspruchte Leichtbau-Strukturen
DE19918210A1 (de) 1999-04-22 2000-11-02 Biomun Gmbh Verfahren zur Herstellung eines Milchpräparates mit verzögerter Inhaltsstoff-Freisetzung und seine Verwendung
PL199861B1 (pl) 1999-04-29 2008-11-28 Nestle Sa Preparat dla niemowląt i sposób wytwarzania preparatu
US6469063B1 (en) * 1999-11-18 2002-10-22 City Of Hope Inhibition of inflammation via inhibition of COX-2 gene transcription
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
FR2808444B1 (fr) 2000-05-05 2004-03-26 Francois Ballestra Utilisation d'une fraction du lait d'equide pour la fabrication d'une composition possedant une activite d'inhibition de la production de l'interleukine-1 et composition ainsi obtenue
US6465509B2 (en) * 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
JP2004522725A (ja) * 2000-12-22 2004-07-29 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 免疫寛容の誘導
US20020169195A1 (en) * 2001-01-26 2002-11-14 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and an HMG-CoA inhibitor and cystine to enhance glutathione
US6589574B2 (en) * 2001-03-19 2003-07-08 Council Of Scientific & Industrial Research Process for preparation of protein-hydrolysate from milk protein
US20030026845A1 (en) * 2001-06-18 2003-02-06 Etzel Lisa R. Process for preparing protein isolate from milk, whey, colostrum, and the like
FR2827290B1 (fr) 2001-07-13 2004-07-09 Pierre Jouan Biotechnologies Sa Procede d'obtention d'une fraction proteique enrichie en tgf-beta sous forme activee, fraction proteique et applications therapeutiques
DE10208034A1 (de) 2002-02-26 2003-09-11 Helmut Otten Medikament sowie kosmetische und dermatologische Zubereitung enthaltend ein Büffelmilchprodukt

Also Published As

Publication number Publication date
CA2537544A1 (en) 2005-03-24
WO2005025335A1 (en) 2005-03-24
CN1849076B (zh) 2010-06-09
BRPI0413714A (pt) 2006-10-17
US8012509B2 (en) 2011-09-06
EP1514482B2 (de) 2016-06-22
EP1514482B1 (de) 2008-09-10
CR8265A (es) 2006-07-14
MXPA06002648A (es) 2006-06-05
US20070110818A1 (en) 2007-05-17
EP1514482A1 (de) 2005-03-16
AR045745A1 (es) 2005-11-09
DE60323489D1 (de) 2008-10-23
AU2004271722A1 (en) 2005-03-24
JP2007505078A (ja) 2007-03-08
AU2004271722B2 (en) 2010-12-16
EP1955602B1 (de) 2018-04-04
EP1955602A1 (de) 2008-08-13
ES2314152T3 (es) 2009-03-16
PT1514482E (pt) 2008-11-19
CN1849076A (zh) 2006-10-18
JP4824560B2 (ja) 2011-11-30
TW200524545A (en) 2005-08-01
CA2537544C (en) 2012-12-11

Similar Documents

Publication Publication Date Title
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ATE554756T1 (de) Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
EP1706146A4 (de) Nährstoffzusammensetzungen und verfahren zur verbesserten wirksamkeit des immunsystems
IL178142A0 (en) Methods of using and compositions comprising immunomodulatory compounos for the treatment and management of skin diseases or disorders
EP1274444A4 (de) Arzneistoffe zur behandlung psychiatrischer oder abusus-bedingter störungen
ATE551100T1 (de) Pharmazeutische zusammensetzung zur behandlung von kardiovaskulären und cerebrovasakulären erkrankungen
ATE429156T1 (de) Nahrungsergänzung zur behandlung von makula degeneration
PL2878297T3 (pl) Leki do leczenia lub zapobiegania chorobom zwłóknieniowym
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
DE602005024160D1 (de) Zucker und/oder zuckeralkohole zur verhinderung und/oder behandlung vaginaler infektionen
EP1578367A4 (de) Zusammensetzungen und verfahren zur behandlung von immunerkrankungen
EP1572116A4 (de) Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
EP1576137A4 (de) Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
EP1851237A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von knochenerkrankungen
DE602004022036D1 (de) Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
ATE407574T2 (de) Fraktionen und zubereitungen aus milch zur behandlung und / oder vorbeugung cox-2 vermittelter krankheiten
ATE431142T1 (de) Arzneimittel zur behandlung und vermeidung neurogener schmerzen
NO20054798D0 (no) Prosessert fettpreparat for forebygging/bedring av livsstils-relaterte sykdommer
DE602005014145D1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1514482

Country of ref document: EP